Genomed (WAR:GEN) E10: zł1.12 (As of Mar. 2026)


WAR:GEN Genomed SA WAR:GEN
75 GF Score
Price zł25.80
GF Value zł37.76
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genomed E10?

Genomed WAR:GEN 75 E10 is zł1.12 as of Mar. 2026. GuruFocus rates WAR:GEN with a GF Score™ of 75/100 and a GF Value™ of zł37.76 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Genomed's adjusted earnings per share data for the three months ended in Mar. 2026 was zł-0.037. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is zł1.12 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Genomed's average E10 Growth Rate was 21.70% per year. During the past 3 years, the average E10 Growth Rate was 22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Genomed was 22.20% per year. The lowest was 19.50% per year. And the median was 20.85% per year.

As of today (2026-06-27), Genomed's current stock price is zł25.80. Genomed's E10 for the quarter that ended in Mar. 2026 was zł1.12. Genomed's Shiller PE Ratio of today is 23.04.

During the past 13 years, the highest Shiller PE Ratio of Genomed was 77.65. The lowest was 19.83. And the median was 40.28.


Genomed  (WAR:GEN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Genomed's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=25.80/1.12
=23.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Genomed was 77.65. The lowest was 19.83. And the median was 40.28.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Genomed E10 Related Terms


Genomed E10 Historical Data

* Premium members only.

The historical data trend for Genomed's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomed E10 Chart

Genomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.63 0.77 0.87 1.15

Genomed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 0.97 1.07 1.15 1.12

WAR:GEN vs TMO, DHR, IDXX: E10 Comparison

For the Diagnostics & Research subindustry, Genomed's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomed Shiller PE Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genomed's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Genomed's Shiller PE Ratio falls into.


WAR:GEN
75GF Score
Genomed SA WAR:GEN
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomed E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genomed's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.037/158.3232*158.3232
=-0.037

Current CPI (Mar. 2026) = 158.3232.

Genomed Quarterly Data

per share eps CPI Adj_EPS
201606 0.004 99.552 0.006
201609 0.161 99.064 0.257
201612 -0.091 100.366 -0.144
201703 0.131 101.018 0.205
201706 0.300 101.180 0.469
201709 0.387 101.343 0.605
201712 0.539 102.564 0.832
201803 0.495 102.564 0.764
201806 0.264 103.378 0.404
201809 0.001 103.378 0.002
201812 0.359 103.785 0.548
201903 -0.129 104.274 -0.196
201906 0.242 105.983 0.362
201909 0.126 105.983 0.188
201912 0.519 107.123 0.767
202003 -0.100 109.076 -0.145
202006 -0.068 109.402 -0.098
202009 0.017 109.320 0.025
202012 0.463 109.565 0.669
202103 -0.240 112.658 -0.337
202106 0.287 113.960 0.399
202109 0.185 115.588 0.253
202112 0.705 119.088 0.937
202203 0.128 125.031 0.162
202206 -0.423 131.705 -0.508
202209 0.162 135.531 0.189
202212 0.390 139.113 0.444
202303 -0.110 145.950 -0.119
202306 -0.233 147.009 -0.251
202309 0.050 146.113 0.054
202312 0.997 147.741 1.068
202403 -0.466 149.044 -0.495
202406 -0.133 150.997 -0.139
202409 0.268 153.439 0.277
202412 1.171 154.660 1.199
202503 0.180 157.021 0.181
202506 0.049 157.509 0.049
202509 1.079 157.998 1.081
202512 1.294 158.323 1.294
202603 -0.037 158.323 -0.037

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of zł1.12 mean?
Genomed (WAR:GEN) has a E10 of zł1.12 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Genomed and its competitors.
Is Genomed's E10 too high?
Genomed's current E10 is zł1.12. Overall, Genomed has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomed's E10 compare to TMO and DHR?
Genomed's E10 of zł1.12 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Diagnostics & Research company?
A good E10 depends on the Medical Diagnostics & Research industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Genomed and its competitors. Genomed's current E10 is zł1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Significantly Undervalued. The stock's GF Value™ is zł37.76, compared to a current price of zł25.80 — trading 31.7% below its estimated fair value. The current E10 is zł1.12. Genomed's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Genomed (WAR:GEN), the current E10 is zł1.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomed (WAR:GEN) Overvalued in 2026?

Based on GuruFocus' analysis, Genomed stock appears to be undervalued. The current stock price of zł25.80 is trading 31.7% below its estimated GF Value™ of zł37.76. GuruFocus considers Genomed to be Significantly Undervalued.

Key valuation signals for WAR:GEN:

  • E10: zł1.12
  • GF Value™: zł37.76 vs. price of zł25.80 (31.7% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genomed Business Description

Address Ulica Ponczowa 12, Warszawa, POL, 02-971
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
75GF Score

Get the complete analysis for WAR:GEN

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł25.80
Price
zł37.76
GF Value